An antibody against ANGPTL4 cut triglycerides by about 40% in a mid-stage trial
MAR001 lowered fasting triglycerides by 39 to 45 percentage points against placebo in a 236-person phase 2b study. It is an early read on a new target, not an approved drug or an outcomes trial.
| Group | Value (%) |
|---|---|
| MAR001 900 mg | 45.3 |
| MAR001 450 mg | 40.5 |
| MAR001 300 mg | 39.1 |
Drug developers have spent years trying to lower triglyceride-rich lipoproteins, the fatty particles that remain a stubborn residual risk for heart disease even when LDL cholesterol is well controlled. A phase 2b trial in The New England Journal of Medicine reports an early result for one more approach: blocking a protein called ANGPTL4 cut fasting triglycerides by roughly 40% against placebo over 12 weeks [s1].
The target
ANGPTL4 — angiopoietin-like protein 4 — inhibits lipoprotein lipase, the enzyme that clears triglycerides from the blood. Block ANGPTL4, the reasoning goes, and lipoprotein lipase works more freely, pulling triglyceride levels down. MAR001 is a monoclonal antibody against ANGPTL4 being developed for exactly that purpose, and this trial is its first substantial efficacy read [s1].
What the trial did
The study was a two-part, phase 2b, double-blind, randomised, placebo-controlled trial; this report covers part A [s1]. Eligible adults had a non-fasting triglyceride level of at least 175 mg per decilitre and a remnant cholesterol level of at least 35 mg per decilitre at initial screening, confirmed by a fasting triglyceride level of at least 150 mg per decilitre and remnant cholesterol of at least 30 mg per decilitre [s1]. Participants were randomly assigned in equal quarters to MAR001 at 300, 450 or 900 mg, or to matching placebo, given under the skin every 4 weeks for 24 weeks [s1]. The primary endpoint was the percent change from baseline in fasting triglycerides at week 12, expressed as the difference from placebo [s1]. The programme is registered as TYDAL-TIMI 78, NCT07028749 [s2].
A total of 236 participants were enrolled — 177 assigned to MAR001 and 59 to placebo — and 235 received at least one dose and were included in the primary efficacy analysis [s1]. Their mean age was 60.4 years, 39% were women, and the median baseline triglyceride level was 249.5 mg per decilitre (interquartile range 210.0 to 313.0) [s1].
What it found
At week 12, the placebo-adjusted least-squares mean reductions in fasting triglycerides were 39.1 percentage points at the 300 mg dose, 40.5 percentage points at 450 mg, and 45.3 percentage points at 900 mg, with P<0.001 for all three comparisons against placebo [s1]. In other words, each dose cut triglycerides by roughly 40% more than placebo did, with a modest gain at the top dose [s1].
On tolerability over the reported period, adverse events occurred in 123 of 177 participants (69%) in the pooled MAR001 group and in 45 of 58 participants (78%) in the placebo group [s1]. The authors' stated conclusion is cautious and precise: inhibiting ANGPTL4 with MAR001 significantly reduced fasting triglyceride levels at 12 weeks [s1].
How to read it
This is a promising early signal, and it should be read as exactly that. It is a phase 2b trial — designed to establish dose and biological effect, not to prove that patients live longer or have fewer heart attacks [s1]. The endpoint is a blood lipid level, a biomarker. The history of triglyceride-lowering is a cautionary one: several agents have lowered triglycerides convincingly and still failed to reduce cardiovascular events in their outcomes trials, so a large drop in a number on a lab report does not guarantee clinical benefit.
Other limits are worth stating plainly. The trial was modest in size, with 235 participants analysed, and short — the primary read is at 12 weeks, within a 24-week dosing course [s1]. It was funded by the drug's developer, Marea Therapeutics [s1]. And because it enrolled people selected for elevated triglycerides and remnant cholesterol, it does not speak to a general population [s1].
What to watch
The questions that matter next are whether the triglyceride reduction holds across the full treatment course and translates into changes in the lipoprotein particles thought to drive risk, how MAR001 compares with the other triglyceride- and ANGPTL3-targeting agents in development, and — the decisive test — whether a cardiovascular outcomes trial shows that lowering triglycerides this way actually prevents events. For now, the honest summary is that an antibody against a new target lowered triglycerides by about 40% over placebo in one mid-stage trial [s1].
This article describes trial results for an investigational drug and is not medical advice. MAR001 is not approved for use.
Sources
- ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels — The New England Journal of Medicine , November 9, 2026
- A Study of MAR001 in Participants With Elevated Triglycerides (TYDAL-TIMI 78) (NCT07028749) — ClinicalTrials.gov
An oral pill cut lipoprotein(a) up to 85.8% — with no evidence yet on events
In the phase 2 KRAKEN trial, muvalaplin lowered lipoprotein(a) by 47.6% to 85.8% over 12 weeks on an intact-particle assay. Eli Lilly funded it, and the trial was not built to measure heart attacks or strokes.
Blood thinners cut events in lower-risk atrial fibrillation, but the numbers are tiny
SINGLE-AF randomised 1,803 South Koreans with borderline stroke risk to a direct oral anticoagulant or nothing. The drug lowered a composite of stroke, bleeding and death at two years, from 1.5% to 0.5%.
Alirocumab slashed cholesterol but not plaque in transplanted hearts
In the investigator-led CAVIAR trial, adding the PCSK9 inhibitor alirocumab to a statin after heart transplant more than halved LDL cholesterol but did not slow coronary plaque growth at one year.
Does colchicine, an old gout drug, prevent heart attacks?
Two trials found low-dose colchicine cut cardiovascular events, and the FDA approved it for heart risk in 2023. Then the largest trial found nothing, leaving the question genuinely unsettled.